Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Bristol-myers Squibb

Karo Bio Ab

Bruce A Ellsworth

William R Ewing

Philip Michael Sher

Gang Wu

Annapurna Pendri

Natesan Murugesan

Chongqing Sun

William N Washburn

Wei Meng

Samuel Gerritz

Elizabeth Anne Jurica

Ximao Wu

Chunjian Liu

Yanting Huang

Zhengxiang Gu

Alicia Regueiro-Ren

Guixue Yu

Jun Shi

Doree F Sitkoff

Andres S Hernandez

Richard B Sulsky

Janak Singh

Jack Z Gougoutas

Chiajen Lai

Xiang-Yang Ye

Wei Wang

Jianxin Feng

Prashant P Deshpande

Amarendra B Mikkilineni

Michael E Randazzo

Gerard Crispino

Theodor W Denzel

Terry Stouch

Ying Wang

Katerina Leftheris

James Aaron Balog

Stephen T Wrobleski

Pratik Devasthale

Denis E Ryono

Susheel Jethanand Nara

Yeheng Zhu

Manoranjan Panda

Johan Malm

Prasada Rao Jalagam

Stephen P O'Connor

Zhenqiu Hong

David S Yoon

Neeraj Garg

Bin Chen

Thomas Ericsson

Mahmoud Rahimi-Ghadim

Zhu Yeheng

Sun Chongqing

Stephen R Johnson

Stephen P O'CONNOR

The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Galectin-3 inhibitors

Small molecule inhibitors of galectin-3

The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of Galectin-3

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

Pyrrolidine GPR40 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

Dihydropyrazole GPR40 modulators

The present invention provides compounds of Formula (I): (Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

The invention provides for compounds of formula I  Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

Tetrahydroquinoline derivatives as cannabinoid receptor modulators

Indole indane amides which are CB2 agonists are provided which have the structure wherein R, R, R, Rand Rare as defined herein, which compounds are useful in treating autoimmune diseases, inflammation, pain, cardiovascular disorders and other diseases mediated by CB2 receptors. A method for preventing or treating such diseases employing the compounds of the invention is also provided.

Indole indane amide compounds useful as CB2 agonists and method

Method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases. and intermediates thereof. The C-aryl glucosides may be complexed with amino acid complex forming reagents.

Methods of producing C-aryl glucoside SGLT2 inhibitors

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

Azabicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, n, and Z are described herein.

Tetrahydroquinoline cannabinoid receptor modulators

Growing community of inventors

Princeton, NJ, United States of America

Bruce A Ellsworth